Rexahn Pharmaceuticals (REXN) Stock Price, Forecast & Analysis
USA - NASDAQ:REXN -
REXN Key Statistics, Chart & Performance
The current stock price of REXN is 1.81 null. In the past month the price decreased by -17.35%. In the past year, price increased by 0.56%.
REXN Latest News, Press Relases and Analysis
About REXN
Company Profile
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
Company Info
Rexahn Pharmaceuticals
15245 SHADY GROVE ROAD SUITE 455
ROCKVILLE MD 20850
CEO: Douglas J. Swirsky
Phone: 240-268-5300
Rexahn Pharmaceuticals / REXN FAQ
What does REXN do?
REXAHN PHARMACTICALS is a biopharmaceutical company leveraging its proprietary technology platform to discover, develop and commercialize innovative treatments for cancer, central nervous system disorders, sexual dysfunction and other unmet medical needs. Rexahn's compounds are designed to uniquely treat various disease states while significantly minimizing side effects in order to allow patients to regain quality of life through therapy.
What is the stock price of Rexahn Pharmaceuticals today?
The current stock price of REXN is 1.81 null. The price decreased by -3.21% in the last trading session.
Does Rexahn Pharmaceuticals pay dividends?
REXN does not pay a dividend.
What is the ChartMill technical and fundamental rating of REXN stock?
REXN has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 2 out of 10.
On which exchange is REXN stock listed?
REXN stock is listed on the Nasdaq exchange.
REXN Technical Analysis
REXN Fundamental Analysis
ChartMill assigns a fundamental rating of 2 / 10 to REXN. REXN has a bad profitability rating. Also its financial health evaluation is rather negative.
REXN Financial Highlights
Over the last trailing twelve months REXN reported a non-GAAP Earnings per Share(EPS) of -1.4100000000000001. The EPS increased by 25.42% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | -553.95% | ||
| ROA | -72.11% | ||
| ROE | N/A | ||
| Debt/Equity | 0 |